Sentinel Node Biopsy May Spare Breast Cancer Patients Axillary Node Dissection

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 11
Volume 6
Issue 11

HAMBURG-In women with operable breast cancer of small size, sentinel node biopsy can be used to predict the status of the axillary lymph nodes and thereby avoid unnecessary axillary dissection, according to a report from the European Institute of Oncology in Milan presented at the Ninth European Cancer Conference (ECCO 9).

HAMBURG—In women with operable breast cancer of small size, sentinel node biopsy can be used to predict the status of the axillary lymph nodes and thereby avoid unnecessary axillary dissection, according to a report from the European Institute of Oncology in Milan presented at the Ninth European Cancer Conference (ECCO 9).

“This method is an important step forward in the search for less aggressive treatments for breast cancer, without loss of information necessary for accurate therapy,” Dr. Viviana Galimberti said at the meeting. This is especially relevant in an era when mammographic screening is detecting much smaller breast tumors that prove to be node negative on histologic examination, she noted.

In their study, the Milan researchers applied lymphoscintigraphy to identify the first node to receive lymph from the tumor area. They marked the skin projection of this sentinel node, and used a handheld, radioguided gamma ray probe to guide them in making a small cutaneous axillary incision through which the sentinel node could be surgically removed. Complete axillary node dissection was then performed through a standard incision.

Sentinel nodes were readily identified and analyzed in 238 of 241 consecutive women with operable breast cancer treated at the European Institute of Oncology. In 109 cases, the sentinel node was positive as were some other nodes, Dr. Galimberti said. In 123 cases, the sentinel node was negative and all other nodes were negative.

In only six cases was the sentinel node free of disease while other nodes were positive for micrometastases. “In two of these six cases, the tumor was multifocal, and in the other four cases, the tumor was monofocal but greater than 1.2 cm in size,” she said. For tumors less than 1.2 cm, the predictive value of sentinel node biopsy was 100%.

In 23 cases, the sentinel node was judged to be negative at the frozen section but later found to be positive for micrometastases on definitive examination. “It is most important that future research should seek more reliable ways of finding microfoci of metastatic cells,” Dr. Galimberti urged.

She cautioned that a randomized controlled trial will be necessary to confirm the safety of routinely abandoning complete axillary dissection in all women with a negative sentinel node.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.